Drug
Kang-lai-te clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2001 (1)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2008 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 3
KangLaiTe USA (3) · First Affiliated Hospital of Harbin Medical University (1) · Jie Li (1) · Zhejiang Kanglaite Pharmaceutical Co.Ltd (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic Agents source
Studies
Open first, then newest update. How each study uses kang-lai-te is read from its arms, and is right about nine times in ten.
Testing it · 6
- Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II StudyCompletedPhase 2First Affiliated Hospital of Harbin Medical UniversityNCT03101514Written as Kanglaite
- Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownPhase 4Jie LiNCT03986528Written as Kanglaite Injection+Chemotherapy
- A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer CachexiaStatus unknownPhase 4Zhejiang Kanglaite Pharmaceutical Co.LtdNCT02553187Written as Kanglaite Injection
- Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic CancerCompletedPhase 2KangLaiTe USANCT00733850Written as Kanglaite Injection plus gemcitabine
- Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung CancerTerminatedPhase 2KangLaiTe USANCT01640730Written as Kanglaite Injection
- Kanglaite Injection Phase I StudyCompletedPhase 1KangLaiTe USANCT00031031Written as Kanglaite Injection (KLT)
Codes
What other systems call kang-lai-te · ClinicalTrials.gg INT004764
- MeSH (NLM) C499781kang-lai-teOne source NLM
- UNII (FDA) YCB6D9ELEQCOIX LACRYMA-JOBI VAR. MA-YUEN SEED OILConfirmed FDA, NLM
- RxNorm 1541732One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C499781 | kang-lai-te | One source NLM |
| UNII (FDA) | YCB6D9ELEQ | COIX LACRYMA-JOBI VAR. MA-YUEN SEED OIL | Confirmed FDA, NLM |
| RxNorm | 1541732 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.